Podcasts

Podcasts

Artificial Intelligence Advances Lymphoma Diagnosis, Biomarker Identification, and Precision Treatment

11/04/2026

Wenchao Han, PhD

Wenchao Han, PhD, discusses the emerging role of artificial intelligence (AI) in lymphoma diagnosis and management, highlighting AI-assisted histopathologic classification, multimodal biomarker analysis, and treatment response prediction, as...

Wenchao Han, PhD, discusses the...

11/04/2026

Oncology

Podcasts

Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice

10/19/2026

David Portnoy, MD, FACP

10/19/2026

Oncology

Podcasts

Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice

10/08/2026

Omid Hamid, MD

10/08/2026

Oncology

Podcasts

Immune Checkpoint Inhibition in Advanced CSCC: Perspectives From Clinical Practice

10/08/2026

Bahar Dasgeb, MD

10/08/2026

Oncology

Podcasts

Preparing for Biomarker-Directed Care in epNEC: What Pathologists Need to Know Now

09/03/2026

David Klimstra, MD

This podcast features Dr David Klimstra discussing how pathologists can prepare for biomarker-directed care in extrapulmonary neuroendocrine carcinoma (epNEC). Key topics include accurate NEC classification before delta-like ligand 3 (DLL3)...

This podcast features Dr David...

09/03/2026

Oncology

Podcasts

Real-World Decision Points in Biomarker-Driven NSCLC Management

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results,...

Dr Jamie Chaft discusses how...

08/05/2026

Oncology

Podcasts

Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Podcasts

Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Podcasts

Experienced Dermatologists Continue to Outperform Artificial Intelligence in Skin Cancer Diagnosis

08/04/2026

Luc Thomas, MD, PhD

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the...

Luc Thomas, MD, PhD, discusses...

08/04/2026

Oncology

Podcasts

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

07/08/2026

Umberto Vitolo, MD

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...

Umberto Vitolo, MD, discusses...

07/08/2026

Oncology

Recent News

FDA Approval

FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma

11/06/2026

Stephanie Holland

Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...

Results from the phase 1b/2...

11/06/2026

Oncology

News

Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit

11/05/2026

Emily Estrada

Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...

Based on results from the phase...

11/05/2026

Oncology

News

Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma

11/05/2026

Emily Estrada

Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...

Following FDA approval supported...

11/05/2026

Oncology

News

Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status

11/04/2026

Emily Estrada

Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...

Results from two phase 2 trials...

11/04/2026

Oncology

News

SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer

11/04/2026

Emily Estrada

Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...

Updated phase 1 results...

11/04/2026

Oncology

News

Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer

11/04/2026

Emily Estrada

Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...

Updated results from a phase 1...

11/04/2026

Oncology

News

Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors

11/04/2026

Emily Estrada

Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...

Results from RINGSIDE trial...

11/04/2026

Oncology

FDA Alerts

Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results

11/04/2026

Stephanie Holland

Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...

Results from the phase 3...

11/04/2026

Oncology

News

Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance

11/03/2026

Stephanie Holland

Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...

Medicare coverage has been...

11/03/2026

Oncology

News

What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium

11/02/2026

Janelle Bradley

The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.

The 2026 NANETS...

11/02/2026

Oncology